GNF4877 --- β Cell Proliferation Inducer

Overview
Catalog #	bs-60294c-10mg-solid
Product Name	GNF4877 --- β Cell Proliferation Inducer
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 494.52 Formula: C25 H27 F N6 O4 CAS Number: 2041073-22-5 InChi Key: UZIATSFXNVOVFE-OAHLLOKOSA-N InChi: InChI=1S/C25H27FN6O4/c1-14(2)36-16-5-6-18(26)17(10-16)19-12-29-23(27)22(30-19)24(33)31-20-11-28-8-7-21(20)32-9-3-4-15(13-32)25(34)35/h5-8,10-12,14-15H,3-4,9,13H2,1-2H3,(H2,27,29)(H,31,33)(H,34,35)/t15-/m1/s1 Smiles: CC(C)OC1C=CC(F)=C(C=1)C1=CN=C(N)C(=N1)C(=O)NC1C=NC=CC=1N1C[C@@H](CCC1)C(O)=O Purity: 98.0 Solubility: DMSO up to 100 mM Appearance: Solid Power. Shelf Life: 1.0 years
Description	GNF4877 is a highly potent and selective small molecule that promotes pancreatic β cell proliferation in rodent （EC50 ~0.66 µM）and human primary islets (EC50 ~0.54 µM), better than its analog GNF7156. It acts most likely as a result of combined inhibition of DYRK1A and GSK3B. GNF4877-treated human islets retain functionality in vitro and after transplantation into diabetic mice. Oral dosing of GNF4877 in diabetic mice induces β-cell proliferation, increases β-cell mass and insulin content, and improves glycaemic control. Biochemical, genetic and cell biology data point to Dyrk1a as the key molecular target. GNF4877 and its analog GNF7156 are the good chemical tools to support the feasibility of treating diabetes with an oral therapy to restore β-cell mass, and highlights a tractable pathway for future drug discovery efforts.